Four drug candidates are in the pipeline at various stages of development:
SH7139’s preclinical evaluation was completed in the first quarter of 2017. Following the preparation and submission of an IND application, it will advance into clinical trials in late 2017.
SH7139 is also being tested for utility in whole body imaging of patients using Positron Emission Tomography.
SH7129 is a biotinylated analog. It has been evaluated as a companion diagnostic to identify patients that should respond to SH7139 therapy.
SH7133 is the free amine analog of SH7139 (no tag present) and it is being evaluated as an oral therapeutic
SH7113 is a bis-bidentate analog of SH7139 that binds bivalently to two neighboring HLA-DR targets.
DeNardo, G., Natarajan, A., Hok, S., Mirick, G., DeNardo, S., Corzett, M., Sysko, V., Lehmann, J., Beckett, L, and Balhorn, R. (2008) Nanomolecular HLA-DR10 Antibody Mimics: A Potent System for Molecular Targeted Therapy and Imaging. Cancer Biotherapy and Radiopharmaceuticals 23: 783-795. (2008)
Balhorn, R. L., Skorupski, K. A., Hok, S., Balhorn, M. (Cosman)., Guerrero, T. & Rebhun, R. B. (2010). A Selective High Affinity Ligand (SHAL) Designed to Bind to an Over-expressed Human Antigen on Non-Hodgkin’s Lymphoma also Binds to Canine B-cell Lymphomas. Vet Immunol Immunopathol. 2010 Oct 15;137(3-4):235-42. doi: 10.1016/j.vetimm.2010.05.014. Epub 2010 Jun 2. (2010)
Baum, R. P.and HR Kulkarni, THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy – The Bad Berka Experience, Theranostics 2012; 2(5):437-447. doi: 10.7150/thno.3645 (2012)
Balhorn, R., Rebhun, R., Hok, S., Baum, R., Sanger, J. & Balhorn, M. (Cosman) Biotinylated derivatives of selective high affinity ligand (SHAL) therapeutics as companion diagnostics for prescreening non-Hodgkin’s lymphoma patients. Proc Amer Assoc Cancer Res, Vol 53, Chicago, IL. AACR 2012 Abstract no. 4591 (2012)
Balhorn, R. & Balhorn, M. (Cosman) Selective High Affinity Ligands (SHALs): A New Class of Targeting Agents for Cancer Imaging and Therapy. In: Medical Radiology, Radiation Oncology, Volume Therapeutic Nuclear Medicine, R.P. Baum, ed., Springer-Verlag, Germany pp. 139-150 (2014)
Balhorn, G. Mirick, G. L. DeNardo, L. Beckett, J. Li, S. Hok, and M. Balhorn, Effect of route and dosing regimen on efficacy of SH7139 in mouse Burkitt’s lymphoma xenografts. Cancer Res 74:2703 (2014); doi:10.1158/1538-7445. (2014)
R. Balhorn, M. (Cosman) Balhorn. Pre-clinical toxicology and safety of SH7139, the first of a new class of targeted therapeutics for non-Hodgkin’s lymphoma and other cancers. Cancer Res 2017:77, in press.
M. (Cosman) Balhorn, R. Balhorn. Therapeutic applications of the selective high affinity ligand drug SH7139 may extend beyond NHL to many other types of solid tumors. Cancer Res 2017: 77, in press.